메뉴 건너뛰기




Volumn 33, Issue 2, 2013, Pages 106-117

Comparison of Mineral Metabolites as Risk Factors for Adverse Clinical Outcomes in CKD

Author keywords

Fibroblast growth factor 23; Parathyroid hormone; Phosphate; Vitamin D

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

EID: 84875250860     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.012     Document Type: Article
Times cited : (11)

References (125)
  • 1
    • 35848968871 scopus 로고    scopus 로고
    • Prevalence of chronic kidney disease in the United States
    • Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
    • (2007) JAMA , vol.298 , pp. 2038-2047
    • Coresh, J.1    Selvin, E.2    Stevens, L.A.3    Manzi, J.4    Kusek, J.W.5    Eggers, P.6
  • 3
    • 84863115528 scopus 로고    scopus 로고
    • Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
    • Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307:674-684.
    • (2012) JAMA , vol.307 , pp. 674-684
    • Thadhani, R.1    Appelbaum, E.2    Pritchett, Y.3    Chang, Y.4    Wenger, J.5    Tamez, H.6
  • 4
    • 68949114585 scopus 로고    scopus 로고
    • KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD)
    • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group
    • KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
    • (2009) Kidney Int Suppl , vol.113
  • 5
    • 79957870135 scopus 로고    scopus 로고
    • Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
    • Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
    • (2011) Kidney Int , vol.79 , pp. 1370-1378
    • Isakova, T.1    Wahl, P.2    Vargas, G.S.3    Gutierrez, O.M.4    Scialla, J.5    Xie, H.6
  • 6
    • 0019890721 scopus 로고
    • The horse-racing effect
    • Peto R. The horse-racing effect. Lancet 1981, 2:467-468.
    • (1981) Lancet , vol.2 , pp. 467-468
    • Peto, R.1
  • 7
    • 84860732514 scopus 로고    scopus 로고
    • Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol
    • Isakova T., Xie H., Barchi-Chung A., Smith K., Sowden N., Epstein M., et al. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol 2012, 7:820-828.
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 820-828
    • Isakova, T.1    Xie, H.2    Barchi-Chung, A.3    Smith, K.4    Sowden, N.5    Epstein, M.6
  • 12
    • 23944460805 scopus 로고    scopus 로고
    • Relationship of phosphorus and calcium-phosphorus product with mortality in CKD
    • Menon V., Greene T., Pereira A.A., Wang X., Beck G.J., Kusek J.W., et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005, 46:455-463.
    • (2005) Am J Kidney Dis , vol.46 , pp. 455-463
    • Menon, V.1    Greene, T.2    Pereira, A.A.3    Wang, X.4    Beck, G.J.5    Kusek, J.W.6
  • 13
    • 77950801451 scopus 로고    scopus 로고
    • Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease
    • Kovesdy C.P., Anderson J.E., Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 2010, 73:268-275.
    • (2010) Clin Nephrol , vol.73 , pp. 268-275
    • Kovesdy, C.P.1    Anderson, J.E.2    Kalantar-Zadeh, K.3
  • 14
    • 79952604526 scopus 로고    scopus 로고
    • Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis
    • Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011, 305:1119-1127.
    • (2011) JAMA , vol.305 , pp. 1119-1127
    • Palmer, S.C.1    Hayen, A.2    Macaskill, P.3    Pellegrini, F.4    Craig, J.C.5    Elder, G.J.6
  • 15
    • 33749261979 scopus 로고    scopus 로고
    • Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease
    • Norris K.C., Greene T., Kopple J., Lea J., Lewis J., Lipkowitz M., et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006, 17:2928-2936.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 2928-2936
    • Norris, K.C.1    Greene, T.2    Kopple, J.3    Lea, J.4    Lewis, J.5    Lipkowitz, M.6
  • 16
    • 33947320099 scopus 로고    scopus 로고
    • Association of disorders in mineral metabolism with progression of chronic kidney disease
    • Schwarz S., Trivedi B.K., Kalantar-Zadeh K., Kovesdy C.P. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:825-831.
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 825-831
    • Schwarz, S.1    Trivedi, B.K.2    Kalantar-Zadeh, K.3    Kovesdy, C.P.4
  • 17
    • 79955555142 scopus 로고    scopus 로고
    • Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction
    • Bellasi A., Mandreoli M., Baldrati L., Corradini M., Di Nicolo P., Malmusi G., et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011, 6:883-891.
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 883-891
    • Bellasi, A.1    Mandreoli, M.2    Baldrati, L.3    Corradini, M.4    Di Nicolo, P.5    Malmusi, G.6
  • 18
    • 80053517709 scopus 로고    scopus 로고
    • FGF23 associates with death, cardiovascular events, and initiation of chronic dialysis
    • Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., et al. FGF23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 1913-1922
    • Kendrick, J.1    Cheung, A.K.2    Kaufman, J.S.3    Greene, T.4    Roberts, W.L.5    Smits, G.6
  • 19
    • 78649445874 scopus 로고    scopus 로고
    • Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study
    • Landray M.J., Emberson J.R., Blackwell L., Dasgupta T., Zakeri R., Morgan M.D., et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010, 56:1082-1094.
    • (2010) Am J Kidney Dis , vol.56 , pp. 1082-1094
    • Landray, M.J.1    Emberson, J.R.2    Blackwell, L.3    Dasgupta, T.4    Zakeri, R.5    Morgan, M.D.6
  • 20
    • 79955015634 scopus 로고    scopus 로고
    • A predictive model for progression of chronic kidney disease to kidney failure
    • Tangri N., Stevens L.A., Griffith J., Tighiouart H., Djurdjev O., Naimark D., et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011, 305:1553-1559.
    • (2011) JAMA , vol.305 , pp. 1553-1559
    • Tangri, N.1    Stevens, L.A.2    Griffith, J.3    Tighiouart, H.4    Djurdjev, O.5    Naimark, D.6
  • 21
    • 80053502175 scopus 로고    scopus 로고
    • Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition
    • Zoccali C., Ruggenenti P., Perna A., Leonardis D., Tripepi R., Tripepi G., et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011, 22:1923-1930.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 1923-1930
    • Zoccali, C.1    Ruggenenti, P.2    Perna, A.3    Leonardis, D.4    Tripepi, R.5    Tripepi, G.6
  • 22
    • 80053525135 scopus 로고    scopus 로고
    • Phosphate REINs in the renoprotective benefit of ACE inhibition
    • Block G.A., Wolf M. Phosphate REINs in the renoprotective benefit of ACE inhibition. J Am Soc Nephrol 2011, 22:1777-1779.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 1777-1779
    • Block, G.A.1    Wolf, M.2
  • 24
    • 34248522825 scopus 로고    scopus 로고
    • Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community
    • Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano J.M., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
    • (2007) Arch Intern Med , vol.167 , pp. 879-885
    • Dhingra, R.1    Sullivan, L.M.2    Fox, C.S.3    Wang, T.J.4    D'Agostino, R.B.5    Gaziano, J.M.6
  • 25
    • 27444436252 scopus 로고    scopus 로고
    • Relation between serum phosphate level and cardiovascular event rate in people with coronary disease
    • Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112:2627.
    • (2005) Circulation , vol.112 , pp. 2627
    • Tonelli, M.1    Sacks, F.2    Pfeffer, M.3    Gao, Z.4    Curhan, G.5
  • 26
    • 63049135405 scopus 로고    scopus 로고
    • Serum phosphorus and cardiovascular mortality in type 2 diabetes
    • Chonchol M., Dale R., Schrier R.W., Estacio R. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med 2009, 122:380-386.
    • (2009) Am J Med , vol.122 , pp. 380-386
    • Chonchol, M.1    Dale, R.2    Schrier, R.W.3    Estacio, R.4
  • 28
    • 84855827125 scopus 로고    scopus 로고
    • Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial
    • Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Kilic S., Eyileten T., et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012, 59:177-185.
    • (2012) Am J Kidney Dis , vol.59 , pp. 177-185
    • Yilmaz, M.I.1    Sonmez, A.2    Saglam, M.3    Yaman, H.4    Kilic, S.5    Eyileten, T.6
  • 29
    • 0035092519 scopus 로고    scopus 로고
    • Parathormone, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients
    • Strozecki P., Adamowicz A., Nartowicz E., Odrowaz-Sypniewska G., Wlodarczyk Z., Manitius J. Parathormone, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001, 23:115-126.
    • (2001) Ren Fail , vol.23 , pp. 115-126
    • Strozecki, P.1    Adamowicz, A.2    Nartowicz, E.3    Odrowaz-Sypniewska, G.4    Wlodarczyk, Z.5    Manitius, J.6
  • 30
    • 0035741826 scopus 로고    scopus 로고
    • Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis
    • Galetta F., Cupisti A., Franzoni F., Morelli E., Caprioli R., Rindi P., et al. Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis. Blood Purif 2001, 19:395-400.
    • (2001) Blood Purif , vol.19 , pp. 395-400
    • Galetta, F.1    Cupisti, A.2    Franzoni, F.3    Morelli, E.4    Caprioli, R.5    Rindi, P.6
  • 31
    • 60449096473 scopus 로고    scopus 로고
    • Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study
    • Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009, 32:37-44.
    • (2009) Kidney Blood Press Res , vol.32 , pp. 37-44
    • Foley, R.N.1    Collins, A.J.2    Herzog, C.A.3    Ishani, A.4    Kalra, P.A.5
  • 32
    • 78651409106 scopus 로고    scopus 로고
    • Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
    • Thadhani R., Appelbaum E., Chang Y., Pritchett Y., Bhan I., Agarwal R., et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011, 33:139-149.
    • (2011) Am J Nephrol , vol.33 , pp. 139-149
    • Thadhani, R.1    Appelbaum, E.2    Chang, Y.3    Pritchett, Y.4    Bhan, I.5    Agarwal, R.6
  • 33
    • 84555187981 scopus 로고    scopus 로고
    • Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study
    • Chue C.D., Edwards N.C., Moody W.E., Steeds R.P., Townend J.N., Ferro C.J. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012, 98:219-224.
    • (2012) Heart , vol.98 , pp. 219-224
    • Chue, C.D.1    Edwards, N.C.2    Moody, W.E.3    Steeds, R.P.4    Townend, J.N.5    Ferro, C.J.6
  • 35
    • 33644812878 scopus 로고    scopus 로고
    • Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study
    • Ayus J.C., Mizani M.R., Achinger S.G., Thadhani R., Go A.S., Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005, 16:2778-2788.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 2778-2788
    • Ayus, J.C.1    Mizani, M.R.2    Achinger, S.G.3    Thadhani, R.4    Go, A.S.5    Lee, S.6
  • 36
    • 33845241514 scopus 로고    scopus 로고
    • Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?
    • Achinger S.G., Ayus J.C. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?. J Am Soc Nephrol 2006, 17:S255-S261.
    • (2006) J Am Soc Nephrol , vol.17
    • Achinger, S.G.1    Ayus, J.C.2
  • 37
    • 34548772315 scopus 로고    scopus 로고
    • Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial
    • Culleton B.F., Walsh M., Klarenbach S.W., Mortis G., Scott-Douglas N., Quinn R.R., et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007, 298:1291-1299.
    • (2007) JAMA , vol.298 , pp. 1291-1299
    • Culleton, B.F.1    Walsh, M.2    Klarenbach, S.W.3    Mortis, G.4    Scott-Douglas, N.5    Quinn, R.R.6
  • 38
    • 66349097180 scopus 로고    scopus 로고
    • Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease
    • Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
    • (2009) Circulation , vol.119 , pp. 2545-2552
    • Gutierrez, O.M.1    Januzzi, J.L.2    Isakova, T.3    Laliberte, K.4    Smith, K.5    Collerone, G.6
  • 40
    • 18144402703 scopus 로고    scopus 로고
    • Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study
    • Young E.W., Albert J.M., Satayathum S., Goodkin D.A., Pisoni R.L., Akiba T., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005, 67:1179-1187.
    • (2005) Kidney Int , vol.67 , pp. 1179-1187
    • Young, E.W.1    Albert, J.M.2    Satayathum, S.3    Goodkin, D.A.4    Pisoni, R.L.5    Akiba, T.6
  • 41
    • 33745210682 scopus 로고    scopus 로고
    • Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
    • Kalantar-Zadeh K., Kuwae N., Regidor D.L., Kovesdy C.P., Kilpatrick R.D., Shinaberger C.S., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
    • (2006) Kidney Int , vol.70 , pp. 771-780
    • Kalantar-Zadeh, K.1    Kuwae, N.2    Regidor, D.L.3    Kovesdy, C.P.4    Kilpatrick, R.D.5    Shinaberger, C.S.6
  • 43
    • 77958471266 scopus 로고    scopus 로고
    • Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD
    • Kovesdy C.P., Kuchmak O., Lu J.L., Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010, 56:842.
    • (2010) Am J Kidney Dis , vol.56 , pp. 842
    • Kovesdy, C.P.1    Kuchmak, O.2    Lu, J.L.3    Kalantar-Zadeh, K.4
  • 45
    • 33644875696 scopus 로고    scopus 로고
    • Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure
    • Markowitz G.S., Stokes M.B., Radhakrishnan J., D'Agati V.D. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005, 16:3389-3396.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 3389-3396
    • Markowitz, G.S.1    Stokes, M.B.2    Radhakrishnan, J.3    D'Agati, V.D.4
  • 46
    • 0021847511 scopus 로고
    • Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil
    • Goligorsky M.S., Chaimovitz C., Rapoport J., Goldstein J., Kol R. Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil. Kidney Int 1985, 27:774-779.
    • (1985) Kidney Int , vol.27 , pp. 774-779
    • Goligorsky, M.S.1    Chaimovitz, C.2    Rapoport, J.3    Goldstein, J.4    Kol, R.5
  • 47
    • 0028205842 scopus 로고
    • Increased nephron oxygen consumption: potential role in progression of chronic renal disease
    • Schrier R.W., Shapiro J.I., Chan L., Harris D.C. Increased nephron oxygen consumption: potential role in progression of chronic renal disease. Am J Kidney Dis 1994, 23:176-182.
    • (1994) Am J Kidney Dis , vol.23 , pp. 176-182
    • Schrier, R.W.1    Shapiro, J.I.2    Chan, L.3    Harris, D.C.4
  • 48
    • 4644221457 scopus 로고    scopus 로고
    • Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    • Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
    • (2004) N Engl J Med , vol.351 , pp. 1296-1305
    • Go, A.S.1    Chertow, G.M.2    Fan, D.3    McCulloch, C.E.4    Hsu, C.Y.5
  • 49
    • 1942506539 scopus 로고    scopus 로고
    • Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies
    • Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004, 15:1307-1315.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 1307-1315
    • Weiner, D.E.1    Tighiouart, H.2    Amin, M.G.3    Stark, P.C.4    MacLeod, B.5    Griffith, J.L.6
  • 50
    • 21644453113 scopus 로고    scopus 로고
    • Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure
    • Neves K.R., Graciolli F.G., dos Reis L.M., Pasqualucci C.A., Moyses R.M., Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004, 66:2237-2244.
    • (2004) Kidney Int , vol.66 , pp. 2237-2244
    • Neves, K.R.1    Graciolli, F.G.2    dos Reis, L.M.3    Pasqualucci, C.A.4    Moyses, R.M.5    Jorgetti, V.6
  • 51
    • 43749124436 scopus 로고    scopus 로고
    • Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease
    • Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008, 73:1296-1302.
    • (2008) Kidney Int , vol.73 , pp. 1296-1302
    • Kovesdy, C.P.1    Ahmadzadeh, S.2    Anderson, J.E.3    Kalantar-Zadeh, K.4
  • 52
    • 67649873051 scopus 로고    scopus 로고
    • Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients
    • Schumock G.T., Andress D.L., Marx S.E., Sterz R., Joyce A.T., Kalantar-Zadeh K. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract 2009, 113:c54-c61.
    • (2009) Nephron Clin Pract , vol.113
    • Schumock, G.T.1    Andress, D.L.2    Marx, S.E.3    Sterz, R.4    Joyce, A.T.5    Kalantar-Zadeh, K.6
  • 53
    • 70349969936 scopus 로고    scopus 로고
    • Elevated serum PTH is independently associated with poor outcomes in older patients with hip fracture and vitamin D inadequacy
    • Fisher A., Goh S., Srikusalanukul W., Davis M. Elevated serum PTH is independently associated with poor outcomes in older patients with hip fracture and vitamin D inadequacy. Calcif Tissue Int 2009, 85:301-309.
    • (2009) Calcif Tissue Int , vol.85 , pp. 301-309
    • Fisher, A.1    Goh, S.2    Srikusalanukul, W.3    Davis, M.4
  • 54
    • 70449532993 scopus 로고    scopus 로고
    • Parathyroid hormone as a mortality predictor in frail aged inpatients
    • Bjorkman M., Sorva A., Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology 2009, 55:601-606.
    • (2009) Gerontology , vol.55 , pp. 601-606
    • Bjorkman, M.1    Sorva, A.2    Tilvis, R.3
  • 56
    • 79955603792 scopus 로고    scopus 로고
    • Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality
    • Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22:956-966.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 956-966
    • Wolf, M.1    Molnar, M.Z.2    Amaral, A.P.3    Czira, M.E.4    Rudas, A.5    Ujszaszi, A.6
  • 57
    • 61749084092 scopus 로고    scopus 로고
    • Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP)
    • Bhuriya R., Li S., Chen S.C., McCullough P.A., Bakris G.L. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009, 53:S3-S10.
    • (2009) Am J Kidney Dis , vol.53
    • Bhuriya, R.1    Li, S.2    Chen, S.C.3    McCullough, P.A.4    Bakris, G.L.5
  • 58
    • 83155180251 scopus 로고    scopus 로고
    • Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study
    • Deo R., Katz R., Shlipak M.G., Sotoodehnia N., Psaty B.M., Sarnak M.J., et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011, 58:1021-1028.
    • (2011) Hypertension , vol.58 , pp. 1021-1028
    • Deo, R.1    Katz, R.2    Shlipak, M.G.3    Sotoodehnia, N.4    Psaty, B.M.5    Sarnak, M.J.6
  • 59
    • 80051619756 scopus 로고    scopus 로고
    • Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
    • Anderson J.L., Vanwoerkom R.C., Horne B.D., Bair T.L., May H.T., Lappe D.L., et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?. Am Heart J 2011, 162:331-3319.e2.
    • (2011) Am Heart J , vol.162
    • Anderson, J.L.1    Vanwoerkom, R.C.2    Horne, B.D.3    Bair, T.L.4    May, H.T.5    Lappe, D.L.6
  • 61
    • 0242403215 scopus 로고    scopus 로고
    • Parathyroid hormone and left ventricular hypertrophy
    • Saleh F.N., Schirmer H., Sundsfjord J., Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003, 24:2054-2060.
    • (2003) Eur Heart J , vol.24 , pp. 2054-2060
    • Saleh, F.N.1    Schirmer, H.2    Sundsfjord, J.3    Jorde, R.4
  • 62
    • 67649223663 scopus 로고    scopus 로고
    • Plasma parathyroid hormone and the risk of cardiovascular mortality in the community
    • Hagstrom E., Hellman P., Larsson T.E., Ingelsson E., Berglund L., Sundstrom J., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119:2765-2771.
    • (2009) Circulation , vol.119 , pp. 2765-2771
    • Hagstrom, E.1    Hellman, P.2    Larsson, T.E.3    Ingelsson, E.4    Berglund, L.5    Sundstrom, J.6
  • 63
    • 79958724181 scopus 로고    scopus 로고
    • Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease
    • Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
    • (2011) JAMA , vol.305 , pp. 2432-2439
    • Isakova, T.1    Xie, H.2    Yang, W.3    Xie, D.4    Anderson, A.H.5    Scialla, J.6
  • 64
    • 84862115472 scopus 로고    scopus 로고
    • PTH-a particularly tricky hormone: why measure it at all in kidney patients?
    • Garrett G., Sardiwal S., Lamb E.J., Goldsmith D.J. PTH-a particularly tricky hormone: why measure it at all in kidney patients?. Clin J Am Soc Nephrol 2012, 7:1-14.
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 1-14
    • Garrett, G.1    Sardiwal, S.2    Lamb, E.J.3    Goldsmith, D.J.4
  • 65
    • 83055172414 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
    • K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
    • (2003) Am J Kidney Dis , vol.42
  • 66
    • 0019459801 scopus 로고
    • Effect of parathyroid hormone on rat heart cells
    • Bogin E., Massry S.G., Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981, 67:1215-1227.
    • (1981) J Clin Invest , vol.67 , pp. 1215-1227
    • Bogin, E.1    Massry, S.G.2    Harary, I.3
  • 67
    • 0030687595 scopus 로고    scopus 로고
    • Effects of excess PTH on nonclassical target organs
    • Bro S., Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997, 30:606-620.
    • (1997) Am J Kidney Dis , vol.30 , pp. 606-620
    • Bro, S.1    Olgaard, K.2
  • 68
    • 77957993384 scopus 로고    scopus 로고
    • PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop
    • Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
    • (2010) Am J Physiol Renal Physiol , vol.299
    • Lavi-Moshayoff, V.1    Wasserman, G.2    Meir, T.3    Silver, J.4    Naveh-Many, T.5
  • 69
    • 80052303008 scopus 로고    scopus 로고
    • Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo
    • Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:636-643.
    • (2011) Bone , vol.49 , pp. 636-643
    • Rhee, Y.1    Bivi, N.2    Farrow, E.3    Lezcano, V.4    Plotkin, L.I.5    White, K.E.6
  • 70
    • 34447514029 scopus 로고    scopus 로고
    • Vitamin D deficiency
    • Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
    • (2007) N Engl J Med , vol.357 , pp. 266-281
    • Holick, M.F.1
  • 73
    • 34250762524 scopus 로고    scopus 로고
    • 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)
    • de Boer I.H., Ioannou G.N., Kestenbaum B., Brunzell J.D., Weiss N.S. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007, 50:69-77.
    • (2007) Am J Kidney Dis , vol.50 , pp. 69-77
    • de Boer, I.H.1    Ioannou, G.N.2    Kestenbaum, B.3    Brunzell, J.D.4    Weiss, N.S.5
  • 74
    • 79959230591 scopus 로고    scopus 로고
    • Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions
    • Isakova T., Gutierrez O.M., Patel N.M., Andress D.L., Wolf M., Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011, 21:295-302.
    • (2011) J Ren Nutr , vol.21 , pp. 295-302
    • Isakova, T.1    Gutierrez, O.M.2    Patel, N.M.3    Andress, D.L.4    Wolf, M.5    Levin, A.6
  • 75
    • 78149359262 scopus 로고    scopus 로고
    • Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    • de Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
    • (2010) Lancet , vol.376 , pp. 1543-1551
    • de Zeeuw, D.1    Agarwal, R.2    Amdahl, M.3    Audhya, P.4    Coyne, D.5    Garimella, T.6
  • 76
    • 69549133632 scopus 로고    scopus 로고
    • Prospective study of serum 25hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults
    • Ginde A.A., Scragg R., Schwartz R.S., Camargo C.A. Prospective study of serum 25hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009, 57:1595-1603.
    • (2009) J Am Geriatr Soc , vol.57 , pp. 1595-1603
    • Ginde, A.A.1    Scragg, R.2    Schwartz, R.S.3    Camargo, C.A.4
  • 77
    • 77956964689 scopus 로고    scopus 로고
    • Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population
    • Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F., et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010, 106:963-968.
    • (2010) Am J Cardiol , vol.106 , pp. 963-968
    • Anderson, J.L.1    May, H.T.2    Horne, B.D.3    Bair, T.L.4    Hall, N.L.5    Carlquist, J.F.6
  • 78
    • 45149090726 scopus 로고    scopus 로고
    • 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study
    • Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
    • (2008) Arch Intern Med , vol.168 , pp. 1174-1180
    • Giovannucci, E.1    Liu, Y.2    Hollis, B.W.3    Rimm, E.B.4
  • 80
    • 77956934530 scopus 로고    scopus 로고
    • Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients
    • Drechsler C., Pilz S., Obermayer-Pietsch B., Verduijn M., Tomaschitz A., Krane V., et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010, 31:2253-2261.
    • (2010) Eur Heart J , vol.31 , pp. 2253-2261
    • Drechsler, C.1    Pilz, S.2    Obermayer-Pietsch, B.3    Verduijn, M.4    Tomaschitz, A.5    Krane, V.6
  • 81
    • 84155162421 scopus 로고    scopus 로고
    • Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients
    • Chitalia N., Recio-Mayoral A., Kaski J.C., Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 2012, 220:265-268.
    • (2012) Atherosclerosis , vol.220 , pp. 265-268
    • Chitalia, N.1    Recio-Mayoral, A.2    Kaski, J.C.3    Banerjee, D.4
  • 82
    • 79954729172 scopus 로고    scopus 로고
    • Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults
    • Harris R.A., Pedersen-White J., Guo D.H., Stallmann-Jorgensen I.S., Keeton D., Huang Y., et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens 2011, 24:557-562.
    • (2011) Am J Hypertens , vol.24 , pp. 557-562
    • Harris, R.A.1    Pedersen-White, J.2    Guo, D.H.3    Stallmann-Jorgensen, I.S.4    Keeton, D.5    Huang, Y.6
  • 83
    • 84888290186 scopus 로고    scopus 로고
    • Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events
    • In press
    • Lishmanov A., Dorairajan S., Pak Y., Chaudhary K., Chockalingam A. Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther 2011, In press.
    • (2011) Am J Ther
    • Lishmanov, A.1    Dorairajan, S.2    Pak, Y.3    Chaudhary, K.4    Chockalingam, A.5
  • 84
    • 77952316154 scopus 로고    scopus 로고
    • Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters
    • Matias P.J., Jorge C., Ferreira C., Borges M., Aires I., Amaral T., et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010, 5:905-911.
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 905-911
    • Matias, P.J.1    Jorge, C.2    Ferreira, C.3    Borges, M.4    Aires, I.5    Amaral, T.6
  • 87
    • 34948869354 scopus 로고    scopus 로고
    • Vitamin D levels and early mortality among incident hemodialysis patients
    • Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
    • (2007) Kidney Int , vol.72 , pp. 1004-1013
    • Wolf, M.1    Shah, A.2    Gutierrez, O.3    Ankers, E.4    Monroy, M.5    Tamez, H.6
  • 88
    • 84455188819 scopus 로고    scopus 로고
    • Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies
    • Zittermann A., Iodice S., Pilz S., Grant W.B., Bagnardi V., Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012, 95:91-100.
    • (2012) Am J Clin Nutr , vol.95 , pp. 91-100
    • Zittermann, A.1    Iodice, S.2    Pilz, S.3    Grant, W.B.4    Bagnardi, V.5    Gandini, S.6
  • 90
    • 40449107836 scopus 로고    scopus 로고
    • Association of activated vitamin D treatment and mortality in chronic kidney disease
    • Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008, 168:397.
    • (2008) Arch Intern Med , vol.168 , pp. 397
    • Kovesdy, C.P.1    Ahmadzadeh, S.2    Anderson, J.E.3    Kalantar-Zadeh, K.4
  • 91
    • 20844459261 scopus 로고    scopus 로고
    • Activated injectable vitamin D and hemodialysis survival: a historical cohort study
    • Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1115-1125
    • Teng, M.1    Wolf, M.2    Ofsthun, M.N.3    Lazarus, J.M.4    Hernan, M.A.5    Camargo, C.A.6
  • 92
    • 83755206845 scopus 로고    scopus 로고
    • Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study
    • Shoben A.B., Kestenbaum B., Levin G., Hoofnagle A.N., Psaty B.M., Siscovick D.S., et al. Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study. Am J Epidemiol 2011, 174:1363-1372.
    • (2011) Am J Epidemiol , vol.174 , pp. 1363-1372
    • Shoben, A.B.1    Kestenbaum, B.2    Levin, G.3    Hoofnagle, A.N.4    Psaty, B.M.5    Siscovick, D.S.6
  • 93
    • 63849098416 scopus 로고    scopus 로고
    • Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004
    • Ginde A.A., Liu M.C., Camargo C.A. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009, 169:626-632.
    • (2009) Arch Intern Med , vol.169 , pp. 626-632
    • Ginde, A.A.1    Liu, M.C.2    Camargo, C.A.3
  • 94
    • 84857813265 scopus 로고    scopus 로고
    • 25-hydroxyvitamin D: a difficult analyte
    • Carter G.D. 25-hydroxyvitamin D: a difficult analyte. Clin Chem 2012, 58:486-488.
    • (2012) Clin Chem , vol.58 , pp. 486-488
    • Carter, G.D.1
  • 96
    • 84862496200 scopus 로고    scopus 로고
    • Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients
    • Bhan I., Powe C.E., Berg A.H., Ankers E., Wenger J.B., Karumanchi S.A., et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012, 82:84-89.
    • (2012) Kidney Int , vol.82 , pp. 84-89
    • Bhan, I.1    Powe, C.E.2    Berg, A.H.3    Ankers, E.4    Wenger, J.B.5    Karumanchi, S.A.6
  • 97
    • 0031749608 scopus 로고    scopus 로고
    • Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats
    • Schwarz U., Amann K., Orth S.R., Simonaviciene A., Wessels S., Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998, 53:1696-1705.
    • (1998) Kidney Int , vol.53 , pp. 1696-1705
    • Schwarz, U.1    Amann, K.2    Orth, S.R.3    Simonaviciene, A.4    Wessels, S.5    Ritz, E.6
  • 98
    • 1242351768 scopus 로고    scopus 로고
    • 1,25Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat
    • Kuhlmann A., Haas C.S., Gross M.L., Reulbach U., Holzinger M., Schwarz U., et al. 1,25Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286:F526-F533.
    • (2004) Am J Physiol Renal Physiol , vol.286
    • Kuhlmann, A.1    Haas, C.S.2    Gross, M.L.3    Reulbach, U.4    Holzinger, M.5    Schwarz, U.6
  • 99
    • 0036073755 scopus 로고    scopus 로고
    • 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system
    • Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
    • (2002) J Clin Invest , vol.110 , pp. 229-238
    • Li, Y.C.1    Kong, J.2    Wei, M.3    Chen, Z.F.4    Liu, S.Q.5    Cao, L.P.6
  • 100
    • 19944425466 scopus 로고    scopus 로고
    • Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems
    • Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288:E125-E132.
    • (2005) Am J Physiol Endocrinol Metab , vol.288
    • Xiang, W.1    Kong, J.2    Chen, S.3    Cao, L.P.4    Qiao, G.5    Zheng, W.6
  • 101
    • 79957485698 scopus 로고    scopus 로고
    • Extra-skeletal effects of vitamin D deficiency in chronic kidney disease
    • Chonchol M., Kendrick J., Targher G. Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med 2011, 43:273-282.
    • (2011) Ann Med , vol.43 , pp. 273-282
    • Chonchol, M.1    Kendrick, J.2    Targher, G.3
  • 102
    • 34548497123 scopus 로고    scopus 로고
    • Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study
    • Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 2600-2608
    • Fliser, D.1    Kollerits, B.2    Neyer, U.3    Ankerst, D.P.4    Lhotta, K.5    Lingenhel, A.6
  • 104
    • 84857088991 scopus 로고    scopus 로고
    • Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women
    • Semba R.D., Fink J.C., Sun K., Cappola A.R., Dalal M., Crasto C., et al. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 2012, 7:85-91.
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 85-91
    • Semba, R.D.1    Fink, J.C.2    Sun, K.3    Cappola, A.R.4    Dalal, M.5    Crasto, C.6
  • 105
    • 77956159370 scopus 로고    scopus 로고
    • FGF23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment
    • Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010, 25:3983-3989.
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 3983-3989
    • Seiler, S.1    Reichart, B.2    Roth, D.3    Seibert, E.4    Fliser, D.5    Heine, G.H.6
  • 106
    • 77952996999 scopus 로고    scopus 로고
    • The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study
    • Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
    • (2010) Ann Intern Med , vol.152 , pp. 640-648
    • Parker, B.D.1    Schurgers, L.J.2    Brandenburg, V.M.3    Christenson, R.H.4    Vermeer, C.5    Ketteler, M.6
  • 107
    • 79955890642 scopus 로고    scopus 로고
    • Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease
    • Taylor E.N., Rimm E.B., Stampfer M.J., Curhan G.C. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011, 161:956-962.
    • (2011) Am Heart J , vol.161 , pp. 956-962
    • Taylor, E.N.1    Rimm, E.B.2    Stampfer, M.J.3    Curhan, G.C.4
  • 108
    • 80755172594 scopus 로고    scopus 로고
    • The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation
    • Seiler S., Cremers B., Rebling N.M., Hornof F., Jeken J., Kersting S., et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011, 32:2688-2696.
    • (2011) Eur Heart J , vol.32 , pp. 2688-2696
    • Seiler, S.1    Cremers, B.2    Rebling, N.M.3    Hornof, F.4    Jeken, J.5    Kersting, S.6
  • 109
    • 84856901155 scopus 로고    scopus 로고
    • FGF23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart
    • Ford M.L., Smith E.R., Tomlinson L.A., Chatterjee P.K., Rajkumar C., Holt S.G. FGF23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012, 27:727-733.
    • (2012) Nephrol Dial Transplant , vol.27 , pp. 727-733
    • Ford, M.L.1    Smith, E.R.2    Tomlinson, L.A.3    Chatterjee, P.K.4    Rajkumar, C.5    Holt, S.G.6
  • 110
    • 84856368350 scopus 로고    scopus 로고
    • FGF23 is associated with cardiac troponin T and mortality in hemodialysis patients
    • 2011
    • Holden R.M., Beseau D., Booth S.L., Adams M.A., Garland J.S., Morton R.A., et al. FGF23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int 2012, 16:53-58. 2011.
    • (2012) Hemodial Int , vol.16 , pp. 53-58
    • Holden, R.M.1    Beseau, D.2    Booth, S.L.3    Adams, M.A.4    Garland, J.S.5    Morton, R.A.6
  • 111
    • 61849155234 scopus 로고    scopus 로고
    • Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients
    • Hsu H.J., Wu M.S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009, 337:116-122.
    • (2009) Am J Med Sci , vol.337 , pp. 116-122
    • Hsu, H.J.1    Wu, M.S.2
  • 112
    • 70450230670 scopus 로고    scopus 로고
    • Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population
    • Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207:546-551.
    • (2009) Atherosclerosis , vol.207 , pp. 546-551
    • Mirza, M.A.1    Larsson, A.2    Melhus, H.3    Lind, L.4    Larsson, T.E.5
  • 113
    • 78649698386 scopus 로고    scopus 로고
    • Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy
    • Canziani M.E., Tomiyama C., Higa A., Draibe S.A., Carvalho A.B. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011, 31:26-32.
    • (2011) Blood Purif , vol.31 , pp. 26-32
    • Canziani, M.E.1    Tomiyama, C.2    Higa, A.3    Draibe, S.A.4    Carvalho, A.B.5
  • 114
    • 79953880208 scopus 로고    scopus 로고
    • Serum fibroblast growth factor-23 (FGF23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients
    • Kirkpantur A., Balci M., Gurbuz O.A., Afsar B., Canbakan B., Akdemir R., et al. Serum fibroblast growth factor-23 (FGF23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011, 26:1346-1354.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 1346-1354
    • Kirkpantur, A.1    Balci, M.2    Gurbuz, O.A.3    Afsar, B.4    Canbakan, B.5    Akdemir, R.6
  • 116
    • 84860387372 scopus 로고    scopus 로고
    • Combined use of vitamin D status and FGF23 for risk stratification of renal outcome
    • Nakano C., Hamano T., Fujii N., Matsui I., Tomida K., Mikami S., et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012, 7:810-819.
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 810-819
    • Nakano, C.1    Hamano, T.2    Fujii, N.3    Matsui, I.4    Tomida, K.5    Mikami, S.6
  • 118
    • 59749105862 scopus 로고    scopus 로고
    • Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis
    • Wesseling-Perry K., Pereira R.C., Wang H., Elashoff R.M., Sahney S., Gales B., et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009, 94:511-517.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 511-517
    • Wesseling-Perry, K.1    Pereira, R.C.2    Wang, H.3    Elashoff, R.M.4    Sahney, S.5    Gales, B.6
  • 119
    • 81755163635 scopus 로고    scopus 로고
    • Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice
    • Farrow E.G., Yu X., Summers L.J., Davis S.I., Fleet J.C., Allen M.R., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011, 108:E1146-E1155.
    • (2011) Proc Natl Acad Sci U S A , vol.108
    • Farrow, E.G.1    Yu, X.2    Summers, L.J.3    Davis, S.I.4    Fleet, J.C.5    Allen, M.R.6
  • 120
    • 80655147297 scopus 로고    scopus 로고
    • Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans
    • Imel E.A., Peacock M., Gray A.K., Padgett L.R., Hui S.L., Econs M.J. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011, 96:3541-3549.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 3541-3549
    • Imel, E.A.1    Peacock, M.2    Gray, A.K.3    Padgett, L.R.4    Hui, S.L.5    Econs, M.J.6
  • 122
    • 78149412578 scopus 로고    scopus 로고
    • Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease
    • Manghat P., Fraser W.D., Wierzbicki A.S., Fogelman I., Goldsmith D.J., Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010, 21:1853-1861.
    • (2010) Osteoporos Int , vol.21 , pp. 1853-1861
    • Manghat, P.1    Fraser, W.D.2    Wierzbicki, A.S.3    Fogelman, I.4    Goldsmith, D.J.5    Hampson, G.6
  • 123
    • 84862095188 scopus 로고    scopus 로고
    • Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease
    • Wahl P., Xie H., Scialla J., Anderson C.A., Bellovich K., Brecklin C., et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 2012, 35:994-1001.
    • (2012) Diabetes Care , vol.35 , pp. 994-1001
    • Wahl, P.1    Xie, H.2    Scialla, J.3    Anderson, C.A.4    Bellovich, K.5    Brecklin, C.6
  • 124
    • 0024324631 scopus 로고
    • Impact of left ventricular hypertrophy on survival in end-stage renal disease
    • Silberberg J.S., Barre P.E., Prichard S.S., Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989, 36:286-290.
    • (1989) Kidney Int , vol.36 , pp. 286-290
    • Silberberg, J.S.1    Barre, P.E.2    Prichard, S.S.3    Sniderman, A.D.4
  • 125
    • 0025280867 scopus 로고
    • Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
    • Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
    • (1990) N Engl J Med , vol.322 , pp. 1561-1566
    • Levy, D.1    Garrison, R.J.2    Savage, D.D.3    Kannel, W.B.4    Castelli, W.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.